NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
January 17, 2022

Nerviano, 17 January 2022

The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.

Dr. Dolgos joins from Servier where he was Global Head of Oncology and a member of the R&D leadership team. Prior to that, he held notable positions at Merck KGaA as Vice President and Head of R&D Strategy PMO, Quantitative Pharmacology and Drug Disposition, setting up strategic directions to best select and ultimately deliver candidate drugs even beyond approval. During the past decades, he has been leading large teams at international top-tier companies like AstraZeneca and Merck KGaA on R&D strategy, R&D governance and capabilities building including Modeling&Simulation, DMPK, Clinical Pharmacology, Bioinformatics, R&D digital, forming alliance, driving changes and creating values for the organizations. In his role, the CEO will focus on the execution of all the activities required to foster the Company’s growth and to enhance its R&D capability.
“I feel privileged to take up the CEO role and to lead the Company reaching its strategic goals and the next sets of milestones, and I truly honor the confidence the Board of Directors have placed in me,” commented Dr. Dolgos. “NMS Group is well known for its experienced team and substantial achievements in bringing molecules for example entrectinib and encorafenib into marketed drugs. I am looking forward to working closely with colleagues and our global partners to ensure that we keep delivering innovative cancer therapies and improve patients’ lives all over the globe” added Dr. Dolgos.
The Shareholder’s Meeting has also set up the new governance structures of the subsidiaries, and granted all the necessary powers to the newly appointed Board of Directors and chief executives respectively:

Nerviano Medical Sciences S.r.l.
Board members: Hugues Dolgos (Chairperson), Guoxian (Gregory) Wu and Barbara Marenco
CEO: Guoxian (Gregory) Wu

Accelera S.r.l. and NerPharMa S.r.l.
Board members: Hugues Dolgos (Chairperson), Angelo Colombo and Enrico Pesenti
CEO: Angelo Colombo

SIMIS S.r.l.
Sole Director: Giuseppe Vivolo

The Company would also like to warmly thank all the members of the Board and executives whose terms of office ended today for their work and commitment in performing their duties in the best interests of the Company and of all its stakeholders.

NMS Group – Shareholders meeting – 17012022 – Final

from NMSGroup


Welcome and Check out our new motion picture!